614 related articles for article (PubMed ID: 10215599)
21. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model.
Ehrich EW; Dallob A; De Lepeleire I; Van Hecken A; Riendeau D; Yuan W; Porras A; Wittreich J; Seibold JR; De Schepper P; Mehlisch DR; Gertz BJ
Clin Pharmacol Ther; 1999 Mar; 65(3):336-47. PubMed ID: 10096266
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of 2 celecoxib derivatives: analgesic effect and selectivity to cyclooxygenase-2/1.
Lu ZH; Xiong XY; Zhang BL; Lin GC; Shi YX; Liu ZG; Meng JR; Zhou YM; Mei QB
Acta Pharmacol Sin; 2005 Dec; 26(12):1505-11. PubMed ID: 16297351
[TBL] [Abstract][Full Text] [Related]
23. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.
Chan CC; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Ford-Hutchinson AW; Forrest MJ; Gauthier JY; Gordon R; Gresser M; Guay J; Kargman S; Kennedy B; Leblanc Y; Leger S; Mancini J; O'Neill GP; Ouellet M; Patrick D; Percival MD; Perrier H; Prasit P; Rodger I
J Pharmacol Exp Ther; 1999 Aug; 290(2):551-60. PubMed ID: 10411562
[TBL] [Abstract][Full Text] [Related]
24. Analysis of prostaglandin G/H synthase-2 inhibition using peroxidase-induced luminol luminescence.
Forghani F; Ouellet M; Keen S; Percival MD; Tagari P
Anal Biochem; 1998 Nov; 264(2):216-21. PubMed ID: 9866686
[TBL] [Abstract][Full Text] [Related]
25. Kinetic modelling of NSAID action on COX-1: focus on in vitro/in vivo aspects and drug combinations.
Goltsov A; Maryashkin A; Swat M; Kosinsky Y; Humphery-Smith I; Demin O; Goryanin I; Lebedeva G
Eur J Pharm Sci; 2009 Jan; 36(1):122-36. PubMed ID: 19028575
[TBL] [Abstract][Full Text] [Related]
26. Inducible cyclooxygenase may have anti-inflammatory properties.
Gilroy DW; Colville-Nash PR; Willis D; Chivers J; Paul-Clark MJ; Willoughby DA
Nat Med; 1999 Jun; 5(6):698-701. PubMed ID: 10371510
[TBL] [Abstract][Full Text] [Related]
27. Glycine-extended gastrin stimulates proliferation and inhibits apoptosis in colon cancer cells via cyclo-oxygenase-independent pathways.
Ogunwobi OO; Beales IL
Regul Pept; 2006 Mar; 134(1):1-8. PubMed ID: 16169610
[TBL] [Abstract][Full Text] [Related]
28. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis.
Jacoby RF; Seibert K; Cole CE; Kelloff G; Lubet RA
Cancer Res; 2000 Sep; 60(18):5040-4. PubMed ID: 11016626
[TBL] [Abstract][Full Text] [Related]
29. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor.
Rao CV; Indranie C; Simi B; Manning PT; Connor JR; Reddy BS
Cancer Res; 2002 Jan; 62(1):165-70. PubMed ID: 11782374
[TBL] [Abstract][Full Text] [Related]
30. Development of a radiochemical cyclooxygenase-1 and -2 in vitro assay for identification of natural products as inhibitors of prostaglandin biosynthesis.
Noreen Y; Ringbom T; Perera P; Danielson H; Bohlin L
J Nat Prod; 1998 Jan; 61(1):2-7. PubMed ID: 9461646
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of cyclooxygenase-2 by celecoxib reverses tumor-induced wasting.
Davis TW; Zweifel BS; O'Neal JM; Heuvelman DM; Abegg AL; Hendrich TO; Masferrer JL
J Pharmacol Exp Ther; 2004 Mar; 308(3):929-34. PubMed ID: 14711936
[TBL] [Abstract][Full Text] [Related]
32. In vivo selectivity of a selective cyclooxygenase 2 inhibitor in the oral surgery model.
Khan AA; Brahim JS; Rowan JS; Dionne RA
Clin Pharmacol Ther; 2002 Jul; 72(1):44-9. PubMed ID: 12152003
[TBL] [Abstract][Full Text] [Related]
33. [Coxibs: cyclooxygenase-2 inhibitors].
Turnheim K
Wien Klin Wochenschr; 2001 Aug; 113(15-16):558-65. PubMed ID: 11571832
[TBL] [Abstract][Full Text] [Related]
34. The COX-2 inhibitor NS-398 causes T-cell developmental disruptions independent of COX-2 enzyme inhibition.
Xu H; Izon DJ; Loftin C; Spain LM
Cell Immunol; 2001 Dec; 214(2):184-93. PubMed ID: 12088417
[TBL] [Abstract][Full Text] [Related]
35. [Clinical application of cyclooxygenase-2 inhibitors].
Dzielska-Olczak M; Olczak S
Pol Merkur Lekarski; 2001 Jun; 10(60):480-2. PubMed ID: 11503270
[TBL] [Abstract][Full Text] [Related]
36. Nonsteroidal anti-inflammatory drugs increase expression of inducible COX-2 isoform of cyclooxygenase in spinal cord of rats with adjuvant induced inflammation.
Hsueh SF; Lu CY; Chao CS; Tan PH; Huang YW; Hsieh SW; Hsiao HT; Chung NC; Lin SH; Huang PL; Lyu PC; Yang LC
Brain Res Mol Brain Res; 2004 Jun; 125(1-2):113-9. PubMed ID: 15193428
[TBL] [Abstract][Full Text] [Related]
37. Petasites hybridus extracts in vitro inhibit COX-2 and PGE2 release by direct interaction with the enzyme and by preventing p42/44 MAP kinase activation in rat primary microglial cells.
Fiebich BL; Grozdeva M; Hess S; Hüll M; Danesch U; Bodensieck A; Bauer R
Planta Med; 2005 Jan; 71(1):12-9. PubMed ID: 15678367
[TBL] [Abstract][Full Text] [Related]
38. Enhancement of opioid inhibition of GABAergic synaptic transmission by cyclo-oxygenase inhibitors in rat periaqueductal grey neurones.
Vaughan CW
Br J Pharmacol; 1998 Apr; 123(8):1479-81. PubMed ID: 9605550
[TBL] [Abstract][Full Text] [Related]
39. Outcome of specific COX-2 inhibition in rheumatoid arthritis.
Lipsky PE; Isakson PC
J Rheumatol Suppl; 1997 Jul; 49():9-14. PubMed ID: 9249645
[TBL] [Abstract][Full Text] [Related]
40. A three-step kinetic mechanism for selective inhibition of cyclo-oxygenase-2 by diarylheterocyclic inhibitors.
Walker MC; Kurumbail RG; Kiefer JR; Moreland KT; Koboldt CM; Isakson PC; Seibert K; Gierse JK
Biochem J; 2001 Aug; 357(Pt 3):709-18. PubMed ID: 11463341
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
